Chronic Myeloid Leukemia Treatment Guidelines
Introduction
- Chronic Myeloid Leukemia (CML) is a type of leukemia characterized by the Philadelphia chromosome and BCR-ABL fusion gene, and progresses through three phases: chronic, accelerated, and blast crisis 1
- Leukemia is broadly classified into four main types: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL) 2
Diagnosis and Initial Treatment
- The clinical presentation of diffuse lymphadenopathy, anemia, leukocytosis, thrombocytopenia, and excess neutrophils and basophils on blood smear suggests CML in chronic phase, and diagnosis should be confirmed with bone marrow examination, cytogenetic analysis for Philadelphia chromosome t(9;22), and molecular testing for BCR-ABL fusion gene 3
- Complete blood count (CBC) is essential for diagnosis, showing leukocytosis, anemia, thrombocytopenia or thrombocytosis 2
- Peripheral blood smear shows presence of blasts and abnormal cell morphology 2
- Bone marrow examination is essential for diagnosis, showing hypercellularity and increased blasts 2
- Cytogenetics is mandatory to detect chromosomal abnormalities like t(9;22) in CML 1
- Molecular studies, including BCR-ABL testing for CML, are crucial for diagnosis and prognosis 2, 4
- Imatinib 400 mg orally daily is the standard first-line therapy for CML due to its high cytogenetic and molecular response rates, lower progression rate to accelerated or blast phase, and good tolerance profile, with 90% overall survival at 54 months 5
- The American Society of Hematology recommends weekly blood counts during the first weeks of therapy, monthly blood counts thereafter, and bone marrow cytogenetics and/or quantitative PCR for BCR-ABL every 6 months to monitor treatment response 3
Monitoring and Response Evaluation
- Evaluate for hematologic response within 3 months, cytogenetic response within 12 months, and molecular response within 18 months of starting imatinib therapy 3
- The European Society for Medical Oncology recommends calculating prognostic scores (Sokal, EURO, or EUTOS) based on age, spleen size, and blood cell counts to guide treatment decisions 1
- Complete hematologic response is defined as WBC <10 x 10^9/L, platelet count <450 x 10^9/L, no immature granulocytes in the differential, and non-palpable spleen, according to the European Society for Medical Oncology 6
- Molecular response is measured by quantitative RT-PCR for BCR-ABL1 transcripts, with major molecular response (MMR) defined as BCR-ABL1 transcripts ≤0.1% by QPCR, and complete molecular response defined as no detectable BCR-ABL1 mRNA, according to the European LeukemiaNet 7
- The following table summarizes the classification of CML:
| Phase | Blasts in Blood or Bone Marrow | Basophils | Platelet Count |
|---|---|---|---|
| Chronic | <10% | <20% | Normal or elevated (100-1000 × 10⁹/L) |
| Accelerated | 10-29% | >20% | Thrombocytosis or thrombocytopenia unrelated to therapy |
| Blast Crisis | ≥30% | - | - |
Treatment of Suboptimal Response or Intolerance
- For patients with suboptimal response or intolerance to imatinib, consider switching to second-generation TKIs (nilotinib or dasatinib) 3
- For younger patients with unfavorable risk factors, consider allogeneic stem cell transplantation as the only known curative treatment, weighing the chance of cure against transplant-related mortality 3, 5
Disease Phase Assessment and Risk Stratification
- Confirm disease phase assessment by evaluating the percentage of blasts in blood and marrow to determine chronic phase, accelerated phase, or blast crisis 1
- The National Comprehensive Cancer Network recommends risk stratification using prognostic scores to guide treatment decisions 1
- The Sokal score and the EUTOS score are used to correlate with disease burden, as stated by the European Society for Medical Oncology 1
Treatment of Advanced Disease
- For patients with accelerated phase or blast crisis, consider higher doses of TKIs or combination therapy, and intensive chemotherapy followed by allogeneic stem cell transplantation when possible 8
- Disease progression is driven by activation of additional oncogenes, inactivation of tumor suppressor genes, amplification of the BCR-ABL fusion gene, and development of BCR-ABL kinase domain mutations, as stated by the European Hematology Association 6
- Early identification of progression markers is crucial, as outcomes are significantly worse in advanced phases, and blast count is the most important prognostic factor, according to the National Comprehensive Cancer Network 6
Prognosis and Follow-up
- Prognosis varies significantly by leukemia type, with 5-year survival ~40% in younger AML patients, <15% in elderly, and 6-year progression-free survival of 84% and overall survival of 88% in CML patients treated with TKIs 2, 9
- Regular monitoring during and after treatment includes complete blood counts, bone marrow examination, molecular monitoring, and long-term surveillance for relapse and treatment-related complications 2, 9